Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Dundee Corp T.DC.A

Alternate Symbol(s):  DDEJF

Dundee Corporation is a Canada-based holding company. Through its operating segments, the Company is a mining- focused investor primarily engaged in acquiring mineral resource assets. Its segments include mining investments, mining services, and corporate and others. Its asset base includes investments in precious and base metals projects across four continents. Its subsidiaries include Dundee Sustainable Technologies Inc. (Dundee Technologies), Dundee Resources Limited, and Goodman & Company, Investment Counsel Inc. The Dundee Sustainable Technologies Inc., a 78%-owned subsidiary developing patented sustainable precious and base metals extraction processes. Through the development of its patented processes, the GlassLock Process and the CLEVR Process, Dundee Technologies extracts precious and base metals from ores and concentrates, while stabilizing contaminants such as arsenic.


TSX:DC.A - Post by User

Post by Macpooron Aug 27, 2022 6:34pm
325 Views
Post# 34924756

TauRx is pleased to announce silver sponsorship of The Clini

TauRx is pleased to announce silver sponsorship of The Clini

CTAD first began in 2008 and is the only meeting focused entirely on Alzheimer’s Disease Therapeutic Trials with key leaders in AD research getting together and forming partnership with the objective of speeding the development of effective treatments to fight the disease.

As well as important therapeutic trial results, clinical trial teams from around the world will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.

TauRx will have a dedicated meeting room at the event, and we look forward to connecting with everyone there.

<< Previous
Bullboard Posts
Next >>